Document Detail


The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.
MedLine Citation:
PMID:  8191394     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since 1985, viral-attenuated blood products have been available for the treatment of patients with hemophilia. Unfortunately, similar viral-attenuated blood products, enriched for von Willebrand factor (vWF), have not been readily available for the treatment of patients with von Willebrand disease (vWD). In the current study, we examined the clinical efficacy and in vivo properties of two viral-attenuated factor VIII products, Koate-HS and Koate-HP, in the treatment of patients with vWD. Twenty-one (21) infusions were evaluated in 17 different vWD patients (4 with type IA; 8 with Type IIA; 1 with Type IID; 4 with type III). Seven (7) patients received Koate-HS and 12 patients received Koate-HP (2 patients received both products; 1 patient was studied three times). Von Willebrand factor antigen, ristocetin cofactor, bleeding time, and the multimeric composition of vWF were determined pre- and post-infusion. Complete or partial correction of prolonged bleeding times was observed in 2 of the 6 patients tested following treatment with Koate-HS and in 7 out of 11 patients tested following treatment with Koate-HP. Surgery was performed on five of these patients, two of whom were treated with Koate-HS and three of whom were treated with Koate-HP. In the surgical patients, clinical hemostasis was achieved regardless of whether the bleeding time was corrected. We conclude that both Koate-HS and Koate-HP can be utilized successfully in the treatment of patients with vWD in spite of the lack of high molecular weight multimers of vWF in these products.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
W T Hanna; R D Bona; C E Zimmerman; C A Carta; G Z Hebert; F R Rickles
Related Documents :
4052324 - Release of vascular plasminogen activator (v-pa) after venous stasis: electrophoretic-z...
21412674 - Is activity loss predictive for development of upper limb oedema after stroke?
16911684 - Clinical significance of measuring blood coagulation factor xiiia regularly and continu...
21679504 - Impact of allergic rhinitis on bronchi: an 8-year follow-up study.
16862824 - Ross procedure: medium-term results.
24775004 - Syncope and bundle branch block. diagnostic yield of a stepped use of electrophysiology...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  71     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  1994 Feb 
Date Detail:
Created Date:  1994-06-23     Completed Date:  1994-06-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  173-9     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Tennessee, Knoxville.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Bleeding Time
Drug Contamination
Factor VIII / chemistry,  isolation & purification,  therapeutic use*
Hemostasis / drug effects
Humans
Male
Middle Aged
Protein Conformation
Safety
Viruses / isolation & purification
von Willebrand Diseases / blood,  drug therapy*,  surgery
von Willebrand Factor / metabolism
Chemical
Reg. No./Substance:
0/von Willebrand Factor; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enhanced thrombin generation in children with sickle cell disease.
Next Document:  Relation of habitual diet and cardiorespiratory fitness to blood coagulation and fibrinolytic factor...